Halabi, S., Roy, A., Rydzewska, L., Godolphin, P., Parmar, M. K. B., Hussain, M. H. A., … Sweeney, C. (2022). Assessing intermediate clinical endpoints (ICE) as potential surrogates for overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 40).

Halabi, Susan, Akash Roy, Larysa Rydzewska, Peter Godolphin, Mahesh K. B. Parmar, Maha H. A. Hussain, Catherine Tangen, et al. “Assessing intermediate clinical endpoints (ICE) as potential surrogates for overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 40, 2022.

Halabi S, Roy A, Rydzewska L, Godolphin P, Parmar MKB, Hussain MHA, et al. Assessing intermediate clinical endpoints (ICE) as potential surrogates for overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC). In: JOURNAL OF CLINICAL ONCOLOGY. 2022.

Halabi, Susan, et al. “Assessing intermediate clinical endpoints (ICE) as potential surrogates for overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC).” JOURNAL OF CLINICAL ONCOLOGY, vol. 40, no. 16, 2022.

Halabi S, Roy A, Rydzewska L, Godolphin P, Parmar MKB, Hussain MHA, Tangen C, Thompson I, Xie W, Carducci MA, Smith MR, Morris MJ, Gravis G, Dearnaley DP, Verhagen P, Goto T, James ND, Buyse ME, Tierney JF, Sweeney C. Assessing intermediate clinical endpoints (ICE) as potential surrogates for overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC). JOURNAL OF CLINICAL ONCOLOGY. 2022.